Abstract:Chemoresistance remains a formidable hurdle against cancer therapy. Seeking for novel therapy strategies is an urgent need for those who no longer benefit from chemotherapy. Chemoresistance is usually associated with the dysfunction of intrinsic apoptosis. Targeting extrinsic apoptosis via TRAIL signaling and the death receptors could be a potential solution to treat chemoresistant cancer. A highly biocompatible nano system for codelivery of the TRAIL DNA and the death receptor sensitizer monensin was developed, in which low-molecular-weight PEI (LMW-PEI) was crosslinked by the sulfhydryl cyclodextrin via disulfide bonds, and then bound with DNA, thus forming the bioreducible polyplex cores. In addition, the cyclodextrin also functioned as a carrier for the hydrophobic monensin via host-guest inclusion. Poly-γ-glutamic acid (γ-PGA) was used to modify the polyplex core via charge interaction. The γ-PGA corona can specifically bind with the tumor-associated gamma-glutamyl transpeptidase (GGT) overexpressed on the tumor cells, and achieve tumor-targeting delivery. Moreover, the tumor-homing peptide RGD-modified γ-PGA was also prepared as the surface coating materials for further improving gene delivery efficiency. This gene delivery system was characterized by the dual ligand-targeting, dual stimuli-responsive features. The ligands of RGD and γ-PGA can target the tumor-associated receptors (i.e., integrin and GGT). The conformation of γ-PGA is pH-sensitive, and the tumor acidic micro environments could trigger the detachment of surface-coating γ-PGA. The disulfide crosslinking LMW-PEI is redox-sensitive, and its fast disassembling in the tumor cells could favor the efficient gene delivery. The anti-tumor efficacy was demonstrated both in vitro and in vivo. Moreover, MYC-mediated synthetic lethality could be an important mechanism for overcoming the drug resistance. An important finding of our studies is the demonstration of the in vivo treatment efficacy of TRAIL/monensin, thus providing a potential novel therapeutic strategy for overcoming drug-resistant cancer.

Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Novel Conjugation of Tumor‐Necrosis‐Factor‐Related Apoptosis‐Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug Delivery

Site-specific PEGylation of a Mutated-Cysteine Residue and Its Effect on Tumor Necrosis Factor (Tnf)-Related Apoptosis-Inducing Ligand (TRAIL).

Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

Multifunctionalized Polyethyleneimine-Based Nanocarriers for Gene and Chemotherapeutic Drug Combination Therapy Through One-Step Assembly Strategy

Enhancement of Anti-Tumor Properties of Trail by Targeted Delivery to the Tumor Neovasculature

Targeting Death Receptors for Drug-Resistant Cancer Therapy: Codelivery of Ptrail and Monensin Using Dual-Targeting and Stimuli-Responsive Self-Assembling Nanocomposites

Biosynthetic cell membrane vesicles to enhance TRAIL-mediated apoptosis driven by photo-triggered oxidative stress

Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle

Long Circulation of PEG-TRAIL Improves Anti-Hepatic Fibrosis Effect of TRAIL Via Targeting Activated Hepatic Stellate Cells

Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine in Vivo

Superior anti-neoplastic activities of triacontanol-PEG conjugate: synthesis, characterization and biological evaluations.

Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity

Cell-Penetrating Peptide Modified PEG-PLA Micelles for Efficient PTX Delivery

Superior TRAIL gene expression and cancer cell apoptosis mediated by highly branched-linear poly(β-amino ester)s

[12]Anen3-Modified Camptothecin and PEGylated AIEgens Co-Assembly into Core-Shell Nanoparticles with ROS/NTR Dual-Response for Enhanced Cancer Therapy.

Improved melanoma suppression with target-delivered TRAIL and PaclitaxSel by a multifunctional nanocarrier.

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Enhancing Cancer Targeting and Anticancer Activity by A Stimulus-Sensitive Multifunctional Polymer-Drug Conjugate